Abstract
BackgroundBusulfan is an alkylating antineoplastic drug extensively used in myeloablative regimens prior to haematopoietic stem cell transplantation. Administration every 6 hours for 4 consecutive days and the low stability of...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
